Edoxaban for Venous Thromboembolism Treatment—The New Kid on The Block for Latin America. A Practical Guide

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramacciotti, Eduardo, Aguiar, Valéria Cristina Resende, Júnior, Valter Castelli, Casella, Ivan Benaducce, Zerati, Antonio Eduardo, Fareed, Jawed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714848/
https://www.ncbi.nlm.nih.gov/pubmed/30486661
http://dx.doi.org/10.1177/1076029618812955
Descripción
Sumario:Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use in the treatment of venous thromboembolism (VTE) in Latin America, following global approvals for this indication. Edoxaban features some particular characteristics when compared to the previously approved DOACs. This review summarizes the main properties of edoxaban, the outcomes results of its pivotal global clinical trials and the peculiar clinical features of this compound. This practical guide aims to help Latin America clinicians understand edoxaban, its proper indication and its use for the appropriate patients with VTE.

Ejemplares similares